BSETrident Texofab LtdHighNeutral
Announced Thu, 12 Feb · 18:02 IST

The Board of Directors inter-alia has approved and taken on record Un-Audited Standalone Financial Results for the quarter and Nine months ended on December 31, 2025 along with Limited Review Report

Revenue DeclinePat Growth 25pctEbitda Margin ExpansionResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Trident Texofab Limited announced its Q3 FY26 and 9M FY26 results approved by the Board on February 12, 2026. Revenue from operations for Q3 FY26 stood at ₹2,514.09 lakhs, down ~20.7% YoY from ₹3,168.94 lakhs; for 9M FY26 it grew ~3.2% YoY to ₹8,445.23 lakhs. Despite the Q3 revenue weakness, Q3 PAT jumped ~90% YoY to ₹57.01 lakhs and 9M PAT grew ~35.8% YoY to ₹271.39 lakhs, driven by lower input/finance costs and improved operating efficiency. EBITDA margin visibly expanded across both periods due to better cost management. The auditor (Shah Kailash & Associates LLP) issued a clean limited review report with no qualifications or emphasis of matter. EPS for 9M FY26 stood at ₹1.85 (vs FY25 full year EPS of ₹2.31). The company continues to operate in a single segment – manufacturing and wholesale trading of grey cloth.

Likely market impact

Mixed picture for shareholders: top-line weakness in Q3 raises demand concerns, but strong bottom-line growth and margin expansion signal improving profitability and cost discipline, which could support the stock in the near term.